or Login to see your representatives.

Access Candidates' and Representatives' Biographies, Voting Records, Interest Group Ratings, Issue Positions, Public Statements, and Campaign Finances

Simply enter your zip code above to get to all of your candidates and representatives, or enter a name. Then, just click on the person you are interested in, and you can navigate to the categories of information we track for them.

Public Statements

Stem Cell Research Enhancement Act of 2005

Location: Washington, DC

STEM CELL RESEARCH ENHANCEMENT ACT OF 2005 -- (House of Representatives - May 24, 2005)


Mr. SALAZAR. Mr. Speaker, I rise today to express my support for the Stem Cell Research Enhancement Act, H.R. 810. I would like to thank Representatives CASTLE and DEGETTE for their leadership on this important issue.

Recent advancements in medical technology have created hope for the millions of people, and their families, who suffer from the effects of diseases like Alzheimer's, Parkinson's, and diabetes. Stem cell research may hold the key to better treatment options, and even a cure, for diseases like these and others.

Many of us will have lasting images of President Ronald Reagan and Christopher Reeves as their frail bodies deteriorated over the years. And I will never forget my own father's battle against Alzheimer's and how his slow deterioration and passing impacted our family. Their personal health battles took on a new meaning as the public debate heated up over the merits and ethics of embryonic stem cell research.

As we look towards the future of medical research, we must always proceed with strict ethical caution. I believe the Castle/DeGette legislation meets this criteria by establishing strict requirements for which new embryonic stem cell lines would be eligible for federal funding. Federal funding of embryonic stem cell research would mean that research could advance at a faster pace while providing stringent requirements and oversight of the research. National and international involvement is needed to ensure research institutions and companies do not intentionally or unintentionally overreach their bounds.



Back to top